“… Cell derivation | Tumor cell targeting | Chemokine recruitment | Targeted region | Cell adhesion molecule for active targeting | Targeted ligand or attractant | Ref. |
Cancer cell | + | − | Cancer cell | EpCAM, galectin-3, N -cadherin | EpCAM, galectin-3, N -cadherin | [61] , [62] , [63] , [64] , [65] , [66] |
WBC | + | + | Cancer cell/TME | CXCR2, CCL18, α4 integrin, endothelin-B receptor, CSF-1 receptor, EGF, VEGFR, TCR | CXCL1/2/3/4/5/7/8, VCAM-1, GM-CSF ET-2, CSF-1, EGFR, VEGF, Melan-A/MART-1, tyrosinase, gp100, MAGEs, so-called cancer/testis antigens, tumor-restricted antigens | [75] , [76] , [77] , [78] , [79] , [80] , [81] , [82] , 90] |
Platelet | + | − | Cancer cell | P-selectin | CD44 receptor | [105 , 106] |
Mesenchymal stem cell | + | + | Cancer cell | CXCR4, EGF, integrins, extracellular matrix molecules | SDF-1, EGFR (HER2) | [108] , [109] , [110] , [111] |
Bacteria | + | − | Cancer cell | HA, engineered anti-HER2 affibody | CD44 receptor, HER2 | [119 , 120] |
Exosome | + | − | Cancer cell | Lysosome-associated membrane glycoprotein 2b, GE-11 peptide, lymphocyte function-associated... |
…”